Submission for OMB Review; Replication of Recovery and Reunification Interventions for Families-Impact Study (New Collection)

Published date14 August 2023
Record Number2023-17364
Citation88 FR 55050
CourtChildren And Families Administration
SectionNotices
55050
Federal Register / Vol. 88, No. 155 / Monday, August 14, 2023 / Notices
and contribute to billions of dollars in
medical and lost productivity costs
every year, the FASTER initiative was
funded to improve the availability and
timeliness of nonfatal firearm injury
data. As the 3-year FASTER initiative
was implemented, the utility of
syndromic surveillance data for
monitoring other forms of nonfatal
violence and mental health conditions
(which may increase risk for or be a
negative outcome associated with
violence victimization) became clear.
Timely state- and local-level data on ED
visits for firearm injuries, other nonfatal
injuries (e.g., intimate partner violence,
sexual violence, child abuse and
neglect), and mental health conditions
are currently limited; thus, the
collection of near real-time data on ED
visits for these conditions at the state-
and local-level could improve the
ability to identify, respond to, and
prevent violence. These data can also be
used to identify, track, and address
disparities in ED visits for firearm
injuries, other violence-related injuries,
and mental health conditions.
The Advancing Violence
Epidemiology in Real Time (AVERT)
initiative, funded by CDC in FY2023,
intends to integrate, expand, and
enhance previous data sharing efforts
with public health departments initiated
under the FASTER program. The goal of
AVERT is to build on the FASTER
program and provide funding to a
minimum of 10 jurisdictions to share
timely ED data for all firearm injuries
(regardless of intent), other violence-
related injuries, and mental health
conditions. AVERT will support states
to conduct routine monitoring of
electronic health record data via
syndromic surveillance to identify ED
visits related to these conditions, as well
as to analyze these data in a timely
manner and share these data with CDC.
To do this, AVERT will leverage ED
syndromic surveillance data already
routinely collected by state health
departments and the District of
Columbia health department through
CDC’s National Syndromic Surveillance
Program (NSSP), which receives near
real-time ED data from health
departments. Descriptive analyses, such
as frequencies and changes in the rate
of ED visits involving a firearm injury,
other violence-related injury, or mental
health condition by region, state, and
local jurisdiction, will be conducted.
Longitudinal statistical analyses will be
used to describe trends.
Understanding the full extent of the
problem of firearm violence, other forms
of nonfatal violence, and mental health
conditions treated in EDs is crucial to
informing prevention and response
strategies and reducing future incidents.
CDC requests OMB approval for an
estimated 30 annual burden hours.
There are no costs to respondents other
than their time.
E
STIMATED
A
NNUALIZED
B
URDEN
H
OURS
Type of
respondent Form name Number of
respondents
Total
number of
responses per
respondent
Average
burden per
response
(hours)
Participating health departments sharing
case-level ED data with CDC. Emergency Department Form (ED Violence
Data Form). 10 6 30/60
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2023–17378 Filed 8–11–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Replication of Recovery and
Reunification Interventions for
Families-Impact Study (New
Collection)
AGENCY
: Office of Planning, Research,
and Evaluation, Administration for
Children and Families, Department of
Health and Human Services.
ACTION
: Request for public comments.
SUMMARY
: The Administration for
Children and Families (ACF) is
proposing a data collection activity as
part of the Replication of Recovery and
Reunification Interventions for
Families-Impact Study (R3-Impact). The
R3-Impact Study aims to satisfy the
legislative requirements called for by
the 2018 SUPPORT for Patients and
Communities Act by replicating and
testing the efficacy of two recovery
coaching interventions for families
engaged in the child welfare system due
to parental substance use disorders.
DATES
: Comments due within 30 days of
publication. The Office of Management
and Budget (OMB) must make a
decision about the collection of
information between 30 and 60 days
after publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
ADDRESSES
: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review-Open
for Public Comments’’ or by using the
search function. You can also obtain
copies of the proposed collection of
information by emailing
OPREinfocollection@acf.hhs.gov.
Identify all requests by the title of the
information collection.
SUPPLEMENTARY INFORMATION
:
Description: The R3-Impact study will
use experimental and quasi-
experimental designs to test the
effectiveness of the recovery coaching
interventions on key child welfare and
parent well-being outcomes. The
implementation study will document
the fidelity of program implementation,
describe the services participants
receive under each approach, and
provide operational lessons gathered
directly from practitioners. These goals
represent ACF’s interest in
understanding whether recovery
coaching interventions yield successful
parental recovery and child welfare
outcomes, and if so, whether the
potential exists to scale the
interventions for the benefit of more
affected families. The proposed
information collection activity consists
of (1) Baseline data collection:
collection of baseline demographic and
parent well-being data from study
participants; (2) Contact form: short
form sent to study participants quarterly
for one year after study enrollment to
keep contact information current and
generally maintain the participant’s
connection to the study; (3) Validation
interviews: short interviews with a
VerDate Sep<11>2014 17:38 Aug 11, 2023 Jkt 259001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\14AUN1.SGM 14AUN1
ddrumheller on DSK120RN23PROD with NOTICES1
55051
Federal Register / Vol. 88, No. 155 / Monday, August 14, 2023 / Notices
subset of study participants to monitor
the quality of data collection interviews
and to validate that the interviewer
spoke with the participant; (4)
Implementation study interviews: using
topic guides, collect information from
program supervisors and frontline staff,
community providers, child welfare
staff, and parents enrolled in the
programs to assess the fidelity of
implementation, document program
services, and gather operational lessons;
and (5) Parent Interview Information
Form: demographic information to
support analysis of parent perspectives
by personal characteristics and history.
Future information collection requests
will be submitted to collect follow-up
data.
Respondents: Parents enrolled in the
R3-Impact Study, and program and
agency staff involved in implementing
the R3 interventions.
A
NNUAL
B
URDEN
E
STIMATES
Instrument
Number of
respondents
(total over
request
period)
Number of
responses per
respondent
(total over
request
period)
Avg. burden
per response
(in hours)
Total burden
(in hours) Annual burden
(in hours)
Baseline Parent Survey .................... 2,750 ................................................ 1 .75 2063 688
Contact Form .................................... 1,843 ................................................ 4 .17 1,253 418
Validation Interviews ......................... 275 ................................................... 1 .08 22 7
Topic Guide–Child Welfare Lead
Staff. 60 ..................................................... 1 1 60 20
Topic Guide–Child Welfare Frontline
Staff. 60 ..................................................... 1 1 60 20
Topic Guide–Partners ....................... 120 ................................................... 1 1 120 40
Topic Guide–Program Managers ...... 60 ..................................................... 1 1.5 90 30
Topic Guide–Mentor Supervisors ..... 60 ..................................................... 1 1.5 90 30
Topic Guide–Parent/Family Mentors 60 ..................................................... 1 1.5 90 30
Topic Guide–Parents ........................ 30 ..................................................... 1 1 30 10
Parent Interview Information Form ... 30 ..................................................... 1 .1 3 1
Estimated Total Annual Burden
Hours: 1,294.
Authority: The Substance Use-
Disorder Prevention that Promotes
Opioid Recovery and Treatment for
Patients and Communities Act
(SUPPORT for Patients and
Communities Act; Pub. L. 115–271)
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2023–17364 Filed 8–11–23; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–2483]
Microbiology Devices Panel of the
Medical Devices Advisory Committee;
Notice of Meeting; Establishment of a
Public Docket; Request for Comments
AGENCY
: Food and Drug Administration,
HHS.
ACTION
: Notice; establishment of a
public docket; request for comments.
SUMMARY
: The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Microbiology Devices
Panel of the Medical Devices Advisory
Committee (the Committee). The general
function of the Committee as a medical
device panel is to provide advice and
recommendations to FDA. In addition,
the Committee will meet to discuss and
provide advice to FDA on in vitro
diagnostic devices used in pandemic
preparedness and response to satisfy, in
part, a requirement under the Food and
Drug Omnibus Reform Act of 2022
(FDORA). The meeting will be open to
the public. FDA is establishing a docket
for public comment on this document.
DATES
: The meeting will be held
virtually on September 7, 2023, from 9
a.m. to 5:15 p.m. Eastern Time and
September 8, 2023, from 9:30 a.m. to
3:45 p.m. Eastern Time.
ADDRESSES
: All meeting participants
will be heard, viewed, captioned, and
recorded for this advisory committee
meeting via an online teleconferencing
and/or video conferencing platform.
Answers to commonly asked questions
about FDA advisory committee meetings
may be accessed at: https://
www.fda.gov/AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FDA is establishing a docket for
public comment on this meeting. The
docket number is FDA–2023–N–2483.
Please note that late, untimely filed
comments will not be considered. The
docket will close on October 10, 2023.
The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of October 10, 2023.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are received on or before that
date.
Comments received on or before
August 30, 2023, will be provided to the
Committee. Comments received after
that date will be taken into
consideration by FDA. In the event that
the meeting is cancelled, FDA will
continue to evaluate any relevant
applications or information, and
consider any comments submitted to the
docket, as appropriate.
You may submit comments as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
VerDate Sep<11>2014 17:38 Aug 11, 2023 Jkt 259001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\14AUN1.SGM 14AUN1
ddrumheller on DSK120RN23PROD with NOTICES1

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT